TROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use

TROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use

Chapter 1: Chapter 1

3 chapters
Play All
ReachMD Healthcare Image
Media formats available:
Program chapters
  • Overview

    Antibody-drug conjugates (ADCs) have promising clinical data in the treatment of advanced non-small cell lung cancer. Listen in as Drs. Benjamin Levy, Rebecca Heist, and Peter Illei discuss current data on TROP2 ADCs and what this means for our patients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 


    Benjamin Levy, MD
    Associate Professor
    Johns Hopkins University
    Washington, DC

    Consulting Fees: Amgen, AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Janssen, Merck, Mirati, Novartis, Pfizer,


    Rebecca Heist, MD, MPH
    Associate Professor of Medicine, Harvard Medical School
    Massachusetts General Hospital
    Boston, MA

    Consulting Fees: AbbVie, Daiichi Sankyo, EMD Serono, Lilly, Novartis, Regeneron, Sanofi
    Research: AbbVie, Agios, Corvus, Daiichi Sankyo, Erasca, Genentech/Roche, Lilly, Mirati, Novartis, Turning Point

    Peter Bela Illei, MD
    Associate Professor of Pathology
    Johns Hopkins University
    Washington, DC

    No relevant relationships reported.

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Brian McDonough, MD, FAAFP, has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Rosanne Strauss, PharmD, MBA, has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Apply guideline-recommended biomarker testing strategies to identify patients with advanced/metastatic NSCLC, with or without actionable mutations, who may experience improved outcomes with emerging TROP2 antibody-drug conjugates (ADCs)
    • Improve efficacy and response to treatment in patients with progressive advanced/metastatic NSCLC with emerging TROP2 ADCs
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, pathologists, and pulmonologists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .50 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  


  • Commercial Support

    This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

Facebook Comments

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free